Shares of Lupin rose over 5%, to Rs545, on reports that the drug maker is expected to soon launch its generic version of the anti-HIV drug, Combivir, in the United States.
The company received a tentative approval last year from the US Food and Drug Administration ( FDA) for the generic drug in two strengths of 150 mg and 300 mg, and is waiting for the final approval from the market regulator,' reports suggest.
The Combivir in the US has a total market size of around $315 million annually, added the report.
....more info
The company received a tentative approval last year from the US Food and Drug Administration ( FDA) for the generic drug in two strengths of 150 mg and 300 mg, and is waiting for the final approval from the market regulator,' reports suggest.
The Combivir in the US has a total market size of around $315 million annually, added the report.
....more info